What is Male Hypogonadism Market Scope?
Hypogonadism occurs when your sex glands produce little or no sex hormones, male hypogonadism or testosterone deficiency is a condition in which the body doesn't produce enough of the hormone that plays a vital role in the development and masculine growth during puberty or enough sperm or both. Sex hormones help control secondary sex characteristics such as testicular development in men, and pubic hair growth and sperm production. According to Boston University School of Medicine, approximately 4 to 5 million men in the United States, are affected with hypogonadism and low testosterone levels are commonly seen in older males. More than 60% of men over 65 years of age have free testosterone levels below the normal values of men between 30 to 35 years of age
The Male Hypogonadism market study is being classified by Type (Primary hypogonadism(Genetic, congenital) and Secondary hypogonadism(Kallman syndrome, pituitary gland tumour)), by Application (Kallmann Syndrome, Klinefelters Syndrome, Pituitary Disorders and Others) and major geographies with country level break-up.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies Research Analyst at AMA predicts that Players from United States will contribute to the maximum growth of Global Male Hypogonadism market throughout the predicted period.
Astrazeneca Plc. (United Kingdom), Merck & Co. Inc. (United States), Laboratories Genevrier (France), Eli Lilly and Company Ltd. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Bayer AG (Germany), Pfizer Inc.(United States), Allergan Plc. (Ireland), Ferring (Switzerland) and AbbVie Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are IBSA Institut Biochimque (Slovakia) and Endo International Plc. (Ireland).
Analyst at AMA have segmented the market study of Global Male Hypogonadism market by Type, Application and Region.
On the basis of geography, the market of Male Hypogonadism has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In February 2020 Clarus Therapeutics announced the launch of new capsule for the male hypogonadism named JATENZO®. JATENZO is the first and only oral softgel testosterone undecanoate, and the first oral testosterone medicine approved by the U.S. FDA in more than 60 years. JATENZO is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
Influencing Market Trend
- High adoption of hormones therapy with increasing cases of hypogonadism
- The increasing number of Cases of Male Hypogonadism Worldwide
- The Increasing Awareness Among Individuals Regarding Hypogonadism Treatment
- Increasing incidence and prevalence of hypogonadism and rise in awareness about hypogonadism
- The adverse effect of the treatment
- High cost associated with the treatment
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Male Hypogonadism Manufacturer, Government Regulatory and Research Organizations and End-Use Industry
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.